Skip to main content
Premium Trial:

Request an Annual Quote

Don Bailey

OncoCyte said in a document filed with the US Securities and Exchange Commission that Don Bailey has tendered his resignation from its board of directors. The firm will recruit a new independent director to fill his spot. No reason was given for his departure. Baily has been on OncoCyte's board since August. He was president and CEO of Questcor Pharmaceuticals from 2007 to 2014. From 1991 to 2000, he was CEO of Comarco, where he also served as its chairman of the board from 1998 to 2007. 

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.